Quantcast

Latest Monoclonal antibodies Stories

2014-03-25 20:22:11

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q29sqz/global_and ) has announced the addition of the "Global and Chinese Monoclonal Antibody Industry Report" [http://www.researchandmarkets.com/research/q29sqz/global_and ] report to their offering. <start_newscom> (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Currently, monoclonal antibody agents have been successfully used in the treatment...

2014-03-25 08:30:28

ROCKVILLE, Md., March 25, 2014 /PRNewswire/ -- VLP Therapeutics, Inc. ("VLP"), a Rockville-based biotechnology company focusing on the research and development of next generation antibody agents and therapeutic as well as preventive vaccines based upon a novel and proprietary i- VLP technology (which stands for "inserted alpha virus like particle"), today announced that Ryuji Ueno, M.D., Ph.D., Ph.D., Co-Founder and former Chair, Chief Executive Officer and Chief Scientific Officer of...

2014-03-25 08:29:17

Resiniferatoxin for Treatment of Pain Associated with Osteosarcoma Veterinary Program Expected to File for MUMS designation in 2014 SAN DIEGO, March 25, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, today announced the formation of a wholly-owned subsidiary, Ark Animal Therapeutics, initially devoted to developing resiniferatoxin (RTX) for multiple veterinary...

2014-03-25 00:23:20

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/llq9cw/investigation) has announced the addition of the "Investigation Report on China Bevacizumab Market, 2009-2018" [http://www.researchandmarkets.com/research/llq9cw/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to...

2014-03-24 23:03:12

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that based on compelling data generated by the SMARTag™ ADC platform, it has increased its minority investment in Redwood Bioscience. The proprietary SMARTag precision protein-chemical engineering platform and novel toxin-linker technologies developed by Redwood enable the generation of homogeneous...

2014-03-24 20:23:49

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the addition of the "Investigation Report on China Rituximab Market, 2009-2018" [http://www.researchandmarkets.com/research/7dhkqb/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Rituximab (trade names ""MabThera"" by Roche, ""Rituxan"" by Genetech) is a chimeric...

2014-03-24 16:25:08

PLANTATION, Fla., March 24, 2014 /PRNewswire/ -- Goodwin Biotechnology, Inc. announced an agreement with Aspyrian Therapeutics, Inc. for the technology transfer, process development, scale-up, and cGMP manufacturing of a novel Antibody Drug Conjugate (ADC) for use in Phase I clinical trials. Aspyrian Therapeutics has secured an exclusive license from the National Cancer Institute for a new ADC technology platform, Near-infrared Photoimmunotherapy (PIT), which permits highly efficient and...

2014-03-24 12:24:47

Surveyed U.S. Payers Also Seek Improvements from New Agents in Effect on Disability, According to Findings from Decision Resources Group BURLINGTON, Mass., March 24, 2014 /PRNewswire/ -- Decision Resources Group finds that new disease-modifying therapies (DMTs) with improved efficacy in slowing disability progression present the greatest opportunity for drug developers in the treatment of relapsing-remitting multiple sclerosis (RR-MS). This finding is based on the relatively high level of...

2014-03-24 08:29:41

SAN FRANCISCO, March 24, 2014 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it will present at the 21(st) Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City. William J. Newell, chief executive officer of...

2014-03-24 08:28:42

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab DENVER, March 24, 2014 /PRNewswire/ -- New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.